CSL Limited Influenza Virus Vaccine — Competitive Intelligence Brief

CSL Limited Influenza Virus Vaccine (CSL Limited Influenza Virus Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed inactivated influenza vaccine Immunology / Infectious Disease Biologic

Target snapshot

CSL Limited Influenza Virus Vaccine (CSL Limited Influenza Virus Vaccine) — Seqirus. This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CSL Limited Influenza Virus Vaccine TARGET	CSL Limited Influenza Virus Vaccine	Seqirus	marketed	inactivated influenza vaccine
Fluarix Tetra Vaccine	Fluarix Tetra Vaccine	GlaxoSmithKline	marketed	Inactivated influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine
High Dose Trivalent Influenza Vaccine	High Dose Trivalent Influenza Vaccine	Brigham and Women's Hospital	marketed	Inactivated influenza vaccine
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
Hualan TIV	Hualan TIV	Sanofi	marketed	Inactivated influenza vaccine
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

1. Seqirus · 3 drugs in this class
2. Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
4. Sinovac Biotech Co., Ltd · 2 drugs in this class
5. La Jolla Institute for Immunology · 1 drug in this class
6. Mount Sinai Hospital, Canada · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. GlaxoSmithKline · 1 drug in this class
10. University of Witwatersrand, South Africa · 1 drug in this class